Company Overview - Novanta is a technology company specializing in advanced photonics, vision, and motion control solutions for medical and industrial OEMs, with nearly $1 billion in trailing twelve-month revenue [6] - The company leverages a broad portfolio of proprietary technologies and brands to address mission-critical applications in high-growth end markets [6] - Novanta's strategic focus on innovation and precision engineering underpins its competitive position in supplying enabling components to leading equipment manufacturers globally [6] Financial Performance - For the trailing twelve months, Novanta reported revenue of $960.31 million and net income of $52.82 million [4] - The company generated $247.8 million in third quarter revenue, reflecting a year-over-year increase of 1.4% [10] - Adjusted EBITDA for the third quarter increased from $57 million to $58.1 million, resulting in a 23.4% margin, while adjusted EPS was reported at $0.87 [10] Market Position and Stock Performance - As of February 12, 2026, Novanta's stock was priced at $139.29, down 5.7% over the past year, underperforming the S&P 500 by 18.63 percentage points [8] - The new position acquired by ACK Asset Management LLC represents 5.6% of the fund's 13F AUM after the trade, indicating a significant allocation towards Novanta [8][12] - The company is positioned within a portfolio that is already tilted toward industrial and infrastructure names, suggesting a strategic focus on sectors with potential growth [12] Future Outlook - Guidance for full-year 2025 revenue is projected to be between $975 million and $979 million, with adjusted EBITDA expected to be between $222 million and $225 million [11] - The key question for investors is whether organic growth will reaccelerate as demand in medical and advanced industrial sectors recovers [12]

Core Insights - Conestoga Capital Advisors sold 168,907 shares of Novanta for approximately $20.1 million in the third quarter, reducing its holdings to just over 1.4 million shares [2][3][7] - Novanta represents 2.3% of Conestoga's reportable U.S. equity assets under management as of September 30, with the stock price at $128.65, down 26% over the past year [3][4] - Novanta's revenue for the trailing twelve months (TTM) is $956.9 million, with a net income of $61.4 million [4] Company Overview - Novanta Inc. specializes in advanced photonics, vision, and precision motion solutions for medical and industrial markets, leveraging a diversified portfolio of proprietary technologies [6][9] - The company generates revenue primarily through sales of proprietary hardware and integrated systems to original equipment manufacturers (OEMs) [9] - Novanta serves global medical and industrial OEMs, targeting sectors such as medical imaging, life sciences, industrial processing, and automation [9] Recent Performance - Novanta's second-quarter results showed flat organic growth and a decline in GAAP profit to $4.5 million from $13.8 million a year prior, although adjusted earnings remained steady at $0.76 per share [11] - Conestoga's decision to reduce its stake in Novanta reflects concerns over the stock's weak performance relative to the market, rather than a loss of confidence in the company's fundamentals [7][10] - The company is noted to be lagging behind cyclical and semiconductor names, indicating sector headwinds affecting its performance [10]